natgillin/translations-raw huggingface dataset:
The CHMP decided that Aprovel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Aprovel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Aranesp’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Aranesp večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Arava’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Arava večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Arixtra’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Arixtra večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Avandamet’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Avandamet večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Avandia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Avandia večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Avastin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Avastin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Avonex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Avonex večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Axura’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Axura večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Azilect’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Azilect večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that BeneFIX’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila BeneFIX večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Betaferon’s benefits are greater than its risks and recommended that Betaferon be granted marketing authorisation.
CHMP je zaključil, da so koristi zdravila Betaferon večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Bondenza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Bondenza večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Bondronat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Bondronat večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Bonviva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Bonviva večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Bridion’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Bridion večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Brilique’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Brilique večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Brinavess’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Brinavess večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Byetta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Byetta večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Caelyx’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Caelyx večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Cayston’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Cayston večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that CellCept’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila CellCept večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Celsentri’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Celsentri večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Celvapan’s benefits of are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi cepiva Celvapan večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ceplene’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ceplene večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Cervarix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi cepiva Cervarix večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Cetrotide’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zaključil je, da so koristi zdravila Cetrotide večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Cialis’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Cialis večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Cimzia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Cimzia večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Clopidogrel Zentiva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Clopidogrel Zentiva večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that CoAprovel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila CoAprovel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Combivir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Combivir večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Conbriza’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Conbriza večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Copalia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Copalia večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Crixivan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Crixivan večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Cubicin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Cubicin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Cystagon’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Cystagon večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Dacogen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Dacogen večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Dafiro’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Dafiro večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that DaTSCAN’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila DaTSCAN večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Docetaxel Winthrop’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Docetaxel Winthrop večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Doribax’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Doribax večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that DuoTrav’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila DuoTrav večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Dynastat’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Dynastat večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Ebixa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ebixa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Effentora’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Effentora večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Efficib’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Efficib večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Efient’s benefits are greater than its risks, when given together with aspirin, for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Efient ob sočasni uporabi z aspirinom za preprečevanje aterotrombotičnih dogodkov pri bolnikih z akutnim koronarnim sindromom, ki so imeli primarno ali odloženo perkutano intervencijo, večje od z njim povezanih tveganj.
The CHMP decided that ellaOne’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila ellaOne večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Elonva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Elonva večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Emend’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Emend večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Enbrel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Enbrel večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Epivir’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Epivir večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Erbitux’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Erbitux večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Evicel’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Evicel večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Exforge’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Exforge večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Exjade’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Exjade večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Extavia’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Extavia večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Fablyn’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Fablyn večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Fabrazyme’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Zaključil je, da so koristi zdravila Fabrazyme večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Fasturtec’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Fasturtec večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Fendrix’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi cepiva Fendrix večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ferriprox’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbora za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Ferriprox večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Fertavid’s benefits are greater than its risks and recommended that Fertavid be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Fertavid večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Firazyr’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Firazyr večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Firdapse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Firdapse večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Focetria’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Focetria večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Foclivia’s benefits are greater than its risk and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Foclivia večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that for patients with Fabry disease treatment with Replagal might provide long- term clinical benefits.
CHMP je menil, da lahko zdravljenje z zdravilom Replagal bolnikom s Fabryjevo boleznijo zagotovi dolgotrajne klinične koristi.
The CHMP decided that Fosavance’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Fosavance večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ganfort’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Ganfort večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Gardasil’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Gardasil večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Glivec’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Glivec večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Glustin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Glustin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that GONAL-f’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila GONAL-f večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Halaven’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Halaven večje od z njim povezanih tveganj, zato je priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Helixate NexGen’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Helixate NexGen večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Herceptin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Herceptin večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Hirobriz Breezhaler’s benefits are greater than its risks and recommended that Hirobriz Breezhaler be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Hirobriz Breezhaler večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Humira’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Humira večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Hycamtin’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Hycamtin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Ilaris’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Ilaris večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Imprida’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Imprida večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Increlex’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Increlex večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CHMP decided that Infanrix hexa’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Infanrix hexa večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Infanrix Penta’s benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Infanrix Penta večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The CHMP decided that Inovelon’s benefits are greater that its risks and recommended that it be given marketing authorisation.
Odbor CHMP je zaključil, da so koristi zdravila Inovelon večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.